

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.455C13APPLICATION NO.  
09/685,696

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Tongtong Wang et al.FILING DATE  
October 9, 2000

GROUP ART UNIT

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SL	AA	5,783,422	07/21/98	Suminami et al.	435	69.3	
SL	AB	5,705,159	01/06/98	Irie et al	424	185.1	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
SL	AC	WO96/30389	10/03/96	WIPO	<input checked="" type="checkbox"/>	<input type="checkbox"/>
SL	AD	WO96/02552	02/01/96	WIPO	<input checked="" type="checkbox"/>	<input type="checkbox"/>

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

SL	AE	Brass et al., "Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma," <i>Human Molecular Genetics</i> , 6(1): 33-39, 1997.
	AF	Database EMBLest17 Accession No. AA340797:EST46165 Fetal kidney II Homo sapiens cDNA 3' end, April 18, 1997.
	AG	Database EMBLest17 Accession No. W22264:Human retina cDNATsp-509I-cleaved sublibrary Homo sapiens cDNA not directional, May 9, 1996.
	AH	Finch et al., "Identification of a cloned sequence activated during multi-stage carcinogenesis in mouse skin," <i>Carcinogenesis</i> , 12(8):1519-1522, August 1991.
	AI	Gerhold and Caskey, "It's the genes! EST access to human genome content," <i>BioEssays</i> 18(12):973-981, 1996.
	AJ	Russell and Barton, "Structural features can be unconserved in proteins with similar folds," <i>J. Mol. Biol.</i> 244:332-350, 1994.
SL	AK	Wells and Peitsch, "The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and expressed sequence tag databases," <i>Journal of Leukocyte Biology</i> 61:545-550, May 1997.

EXAMINER

Shin-Lin Chen

DATE CONSIDERED

2-28-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.455C13APPLICATION NO.  
09/685,696

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)


APPLICANTS

Tongtong Wang et al.

FILING DATE

October 9, 2000

GROUP ART UNIT



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
42	BB	WO 99/47674	09/23/99	WIPO		
	BC	WO 99/38973	08/05/99	WIPO		
	BD	WO 98/46788	10/22/98	WIPO		
	BE	WO 98/35985	08/20/98	WIPO		
	BF	WO 97/07244	02/27/97	WIPO		
	BG	WO 96/28473	09/19/96	WIPO		
	BH	EP0695760A1	02/07/96	European Patent Office		
	BI	WO 95/21862	08/17/95	WIPO		
	BJ	WO 94/06929	03/31/94	WIPO		
52	BK	WO 91/18926	12/12/91	WIPO		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

52	BL	Baldi et al., "Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer," <i>Clinical Cancer Research</i> 3(10):1691-1697, October 1997.
1	BM	Database EMBL Nucleotide and Protein Sequence, Accession No. AI468638, March 17, 1999.
	BN	Davidson et al., "Lung tumours immunoreactive for parathyroid hormone related peptide: analysis of serum calcium levels and tumour type," <i>Journal of Pathology</i> 178:398-401, January 1996.
52	BO	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 $\alpha$ in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.

EXAMINER

Shin-Lin Chen

DATE CONSIDERED

2-28-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.455C13		APPLICATION NO. 09/685,696		
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				APPLICANTS Tongtong Wang et al.				
				FILING DATE October 9, 2000		GROUP ART UNIT		
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	CA							
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION			
					YES	NO		
	CB							
<b>OTHER PRIOR ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)								
SL	CC		Henderson et al., "Identification of lung tumor antigens for cancer immunotherapy: immunological and molecular approaches," <i>Immunological Investigation</i> 29(2):87-91, May 2000.					
	CD		Hogan et al., "The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene," <i>Cancer Research</i> 58(22):5144-5150, November 15, 1998.					
	CE		Hu et al., "A small proline-rich protein, spr1: specific marker for squamous lung carcinoma," <i>Lung Cancer</i> 20:25-30, 1998.					
	CF		Lelievre et al., "Structural properties of chimeric peptides containing a T-cell epitope linked to a fusion peptide and their importance for in vivo induction of cytotoxic T-cell responses," <i>European Journal of Biochemistry</i> 249(3):895-904, 1997.					
	CG		Marshall and Hodgson, "DNA chips: an array of possibilities," <i>Nature Biotechnology</i> 16:27 31, January 1998.					
	CH		Pastor et al., "Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis," <i>Eur. Respir J.</i> 10(3):603-609, March 1997.					
	CI		Rammensee et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 41:178-228, 1995.					
SL	CJ		Ramsay, G., "DNA chips: state-of-the art," <i>Nature Biotechnology</i> 16:40-44, January 1998.					
EXAMINER Shin-Lin Chen				DATE CONSIDERED 2-28-02				
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).								

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. <b>210121.455C13</b>		APPLICATION NO. <b>09/685,696</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>				APPLICANTS <b>Tonglong Wang et al.</b>		GROUP ART UNIT	
				FILING DATE <b>October 9, 2000</b>			
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
DA							
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION YES NO	
DB							
<b>OTHER PRIOR ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
LM	DC	Ruppert et al., "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules," <i>Cell</i> 74:929-937, September 10, 1993.					
	DD	Skeiky et al., "Cloning, expression and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis," <i>Infection and Immunity</i> 67(8):3998-4007, August 1999.					
	DE	Theobald et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Acad. Sci. USA</i> 92:11993-11997, December 1995.					
	DF	Visseren et al., "Identification of HLA-A *0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product," <i>International Journal of Cancer</i> 73(1):125-130, 1997.					
LM	DG	Wang et al., "Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis," <i>Oncogene</i> 19(12):1519-1528, March 16, 2000.					
	DH						
	DI						
	DJ						
EXAMINER <b>Shin-Lin Chen</b>				DATE CONSIDERED <b>2-28-02</b>			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							